Moreover, the large randomized controlled Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) emphasized the role of IL-1b in cardiovascular risk and outcome, demonstrating that its inhibition with canakinumab significantly reduces the recurrence of new cardiovascular events in subjects with stable CAD and persistent increase in CRP (36). Here, CRP is linked to coronary artery disorder.